Corvus Pharmaceuticals (CRVS) Total Liabilities: 2022-2025
Historic Total Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $8.7 million.
- Corvus Pharmaceuticals' Total Liabilities fell 81.24% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 81.24%. This contributed to the annual value of $36.3 million for FY2024, which is 429.03% up from last year.
- According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Total Liabilities is $8.7 million, which was down 5.71% from $9.2 million recorded in Q2 2025.
- Corvus Pharmaceuticals' 5-year Total Liabilities high stood at $46.4 million for Q3 2024, and its period low was $6.7 million during Q1 2024.
- Its 3-year average for Total Liabilities is $14.8 million, with a median of $9.2 million in 2025.
- Per our database at Business Quant, Corvus Pharmaceuticals' Total Liabilities surged by 506.38% in 2024 and then tumbled by 81.24% in 2025.
- Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Total Liabilities stood at $12.1 million in 2022, then plummeted by 43.35% to $6.9 million in 2023, then spiked by 429.03% to $36.3 million in 2024, then plummeted by 81.24% to $8.7 million in 2025.
- Its last three reported values are $8.7 million in Q3 2025, $9.2 million for Q2 2025, and $10.1 million during Q1 2025.